ASX Announcement
13 November 2026

Eye To Present @ Bell Potter Healthcare Conference 2026

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to advise that it will present at the Bell Potter Healthcare Conference 2026 on **Tuesday, 17 November 2026, at 3:00 pm AEDT**.

Managing Director Tom Spurling will present live and provide an update on Nova Eye Medical's business, growth strategy and upcoming catalysts, followed by a live Q&A session.

Hosted by Bell Potter, the virtual conference will run from 17 to 19 November 2026 and will feature presentations from 48 ASX-listed healthcare companies across the biotechnology, medical device, healthcare software and diagnostics sectors.

Presentation Details

- **Date: Tuesday, 17 November 2026**
- **Time: 3:00 pm AEDT (Session 4)**
- **Presenter: Tom Spurling, Nova Eye Medical Managing Director**
- **Format: Virtual live-stream via Bell Potter Client Access**

How to View the Conference

The virtual conference will be exclusively available to live-stream on Bell Potter Client Access. Investors can view the presentation by logging in to Client Access and selecting the Healthcare Conference 2026 tab in the top navigation.

Investors without a Client Access account can register prior to the conference or ask their Bell Potter adviser to set up an account. For assistance, contact your Bell Potter adviser or call 1300 0 BELLS (23557).

Further information, including the conference schedule, is available on the Bell Potter website.

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

-ENDS-

For more information:

Company
Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Investors
Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com